Antithrombotic and thrombolytic therapy for ischemic stroke

Clinics in Geriatric Medicine

Volumn 17, Issue 1, 2001, Pages 149-161

  Savitz, Sean I ^a   Gupta, Gaurav ^b   Singh, Manjeet ^b   Rosenbaum, Daniel M ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROSTAGLANDIN SYNTHASE; SARUPLASE; THROMBOXANE A2; TICLOPIDINE; WARFARIN;

AGED; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; HUMAN; META ANALYSIS; RASH; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA;

EID: 0035109997     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(05)70111-7     Document Type: Article

References (55)

1. Antiplatelet therapy: New foundations for optimal treatment decisions
2. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: A meta-analysis of randomized controlled trials
4. Thrombotic thrombocytopenic purpura associated with clopidogrel
5. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks
6. Primary prevention of stroke
7. Immediate anticoagulation with heparin for first-ever ischemic stroke in the carotid artery territories observed within 5 hours of onset
8. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke
9. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
10. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
11. Cerebral Embolism Task Force: Cardiogenic brain embolism
12. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial
13. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset
14. Cooling therapy for acute stroke
15. Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin
16. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
17. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke
18. Controversies in stroke: Past and present. The Willis Lecture
19. Observations of the fundus oculi in transient monocular blindness
20. Intra-arterial prourokinase for acute ischemic stroke
21. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
22. Therapeutic benefit: Aspirin revisited in light of the introduction of clopidogrel
23. Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association
24. Prevention of stroke with ticlopidine: Who benefits most?
25. Failure of heparin to prevent progression in progressing ischemic infarction
26. Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease
27. Ticlopidine's mechanism of action on platelets
28. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
29. Aspirin for the primary prevention of stroke and other major vascular events: Meta-analysis and hypotheses
30. Aspirin wars: The optimal dose of aspirin to prevent stroke
31. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
32. Prospective study of aspirin use and risk of stroke in women
33. Effects of tissue plasminogen activator for acute ischemic stroke at one year
34. Hemorrhagic transformation in acute ischemic stroke
35. Anticoagulant, antithrombotic and thrombolytic drugs
36. Multicenter trials of a novel modified t-PA, E6010 by I.V. bolus injection in patients with acute carotid artery territory stroke
37. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study
38. Treatment of acute ischemic stroke: Open trial with continuous intravenous heparinization
39. Risk factors, outcomes, and stroke subtypes for ischemic stroke
40. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: Outpatient management for adults
41. Arteriosclerosis and the promise of GPIIb /IIIa inhibitors in stroke
42. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study
43. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting
44. Intravenous heparin for acute stroke: What can we learn from the megatrials?
45. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience
46. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack on minor ischemic stroke
47. A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
48. Tissue plasminogen activator for acute ischemic stroke
49. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
50. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
51. The Swedish Aspirin Low-Dose Trial: Seventy five mg aspirin as secondary prophylaxis after cerebrovascular ischemic events
52. United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial final results
53. Dipyridamole plus aspirin in cerebrovascular disease